C4 Therapeutics, Inc.
C4 Therapeutics, Inc. (CCCC) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cccc · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for C4 Therapeutics, Inc. (CCCC) measures how much investors pay for each dollar of the company's trailing earnings. CCCC's current PE ratio of N/A is calculated by dividing its stock price of $3.59 by its TTM earnings per share of -$0.82.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
C4 Therapeutics, Inc.You CCCC | $297M | N/A | — | -$0.82 |
 Armata Pharmaceuticals, Inc. ARMP | $278M | N/A | — | -$4.80 |
 Codexis, Inc. CDXS | $237M | N/A | — | -$0.50 |
 Cybin Inc. CYBN | $413M | N/A | — | -$0.61 |
 Insight Molecular Diagnostics Inc. IMDX | $154M | N/A | — | -$1.65 |
 Milestone Pharmaceuticals Inc. MIST | $106M | N/A | — | -$0.75 |
 Molecular Partners AG MOLN | $148M | N/A | — | -$1.65 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.27 | — | |
2024-12-31 FY2024 | — | $-1.52 | — | |
2023-12-31 FY2023 | — | $-2.67 | — | |
2022-12-31 FY2022 | — | $-2.62 | — | |
2021-12-31 FY2021 | — | $-1.82 | — | |
2020-12-31 FY2020 | — | $-1.54 | — | |
2019-12-31 FY2019 | — | $-0.79 | — | |
2018-12-31 FY2018 | — | $-1.06 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for C4 Therapeutics, Inc. (CCCC) measures how much investors pay for each dollar of the company's trailing earnings. CCCC's current PE ratio of N/A is calculated by dividing its stock price of $3.59 by its TTM earnings per share of -$0.82.
Frequently asked questions
CCCC pe ratio · 6 questionsCCCC's current PE ratio is N/A as of 2026-06-08, based on a stock price of $3.59 and TTM EPS of -$0.82. Data sourced from Financial Modeling Prep via CCCC's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · C4 Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08